Trial Profile
An Evaluation of the Efficacy Beyond Progression of Vemurafenib Combined With Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600 Mutation-positive Metastatic Melanoma in Focal Progression With First-line Combined Vemurafenib and Cobimetinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary) ; Nivolumab; Pembrolizumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Dec 2021 Planned End Date changed from 3 Apr 2021 to 29 Apr 2023.
- 01 Dec 2021 Planned primary completion date changed from 3 Apr 2021 to 29 Apr 2023.
- 01 Dec 2021 Status changed from recruiting to active, no longer recruiting.